Adaptive Biotechnologies Corp vs Simon Property Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while Simon Property Group Inc trades at $220.46 (market cap $71.03B). The key difference: Simon Property Group Inc is far larger — about 17.6× Adaptive Biotechnologies Corp's market cap, and Simon Property Group Inc pays a 4.05% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | SPG | |
|---|---|---|
Market Cap | $4.04B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $25.45 | $236.70 |
52-Week Low | $12.30 | $169.22 |
Enterprise Value | $4.10B | $99.48B |
Dividend Yield | — | 4.05% |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Simon Property Group (SPG) trades at $220.37, down 0.08% on the day, with a bearish technical signal but strong fundamentals. Recent Q2 2026 earnings showed an EPS miss ($1.49 actual vs. $1.64 expected), though FFO beat estimates and full-year guidance was raised. The company maintains robust profitability with a net income margin of 66.57% and pays consistent dividends.
Outlook is mixed: solid operational performance and raised guidance support upside near the $226.58 consensus price target, but high debt ($24.21B) and economic sensitivity pose risks. Analyst sentiment leans neutral with 54.05% hold ratings, reflecting cautious optimism amid macroeconomic uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →